← Leaderboards
Anna Schwendeman
University Of Kentucky
$12,478,662
Attributed
$19,423,932
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,173,932 · 7
FDA$7,250,000 · 2
By mechanism
R01$8,211,541 · 3
U18$5,250,000 · 1
T32$3,104,391 · 2
U01$2,000,000 · 1
R21$858,000 · 2
Top collaborators
- James E Polli6 shared
- Xiang-An Li5 shared
- Yuqing E Chen4 shared
- Yanhong Guo4 shared
- Maria G Castro1 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Deneys Rem Van Der Westhuyzen$5,875,172
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoMacrophageDrug KineticsMediatingPathway InteractionsHigh Density LipoproteinsEffective TherapySafetyBiotechnologyBaseDosePlayLipidsFormulationDesignPathogenesisReportingClinical TrialsEventCause Of DeathIn VitroAnimal ModelNovel TherapeuticsParticle
Grant awards (28)
Development of phospholipid-based nanotherapeutics for treating abdominal aortic aneurysm$763,935
R01 · FY2025 · HL
Cellular Biotechnology Training Program (CBTP) - Years 31-35$534,450
T32 · FY2025 · GM · contact PI
Center for Research on Complex Generics$1,000,000
U18 · FY2024 · FD
Development of phospholipid-based nanotherapeutics for treating abdominal aortic aneurysm$748,657
R01 · FY2024 · HL
Cellular Biotechnology Training Program (CBTP) - Years 31-35$549,359
T32 · FY2024 · GM · contact PI
Development of phospholipid-based nanotherapeutics for treating abdominal aortic aneurysm$81,335
R01 · FY2024 · HL
Center for Research on Complex Generics$1,000,000
U18 · FY2023 · FD
Development of phospholipid-based nanotherapeutics for treating abdominal aortic aneurysm$763,935
R01 · FY2023 · HL
Cellular Biotechnology Training Program (CBTP) - Years 31-35$530,535
T32 · FY2023 · GM · contact PI
Center for Research on Complex Generics$250,000
U18 · FY2023 · FD
Systematic Analytical Characterization of Innovator and Biosimilar Products with the Focus on Post-translational Modifications$2,000,000
U01 · FY2022 · FD · contact PI
Center for Research on Complex Generics$1,000,000
U18 · FY2022 · FD
Cellular Biotechnology Training Program (CBTP) - Years 31-35$520,362
T32 · FY2022 · GM · contact PI
Center for Research on Complex Generics$1,000,000
U18 · FY2021 · FD
Cellular Biotechnology Training Program (CBTP)$487,629
T32 · FY2021 · GM · contact PI
Chemo-immunotherapy strategy for pediatric high grade glioma$429,000
R21 · FY2021 · NS
Center for Research on Complex Generics$1,000,000
U18 · FY2020 · FD
KLF14 and Atherosclerosis$706,887
R01 · FY2020 · HL
Cellular Biotechnology Training Program (CBTP)$482,056
T32 · FY2020 · GM · contact PI
KLF14 and Atherosclerosis$706,887
R01 · FY2019 · HL
Synthetic HDL_a potential sepsis therapy$603,893
R01 · FY2019 · GM
Optimization of synthetic HDL nanoparticles for treatment Niemann-Pick Type C$429,000
R21 · FY2019 · NS · contact PI
KLF14 and Atherosclerosis$705,755
R01 · FY2018 · HL
Synthetic HDL_a potential sepsis therapy$603,893
R01 · FY2018 · GM
KLF14 and Atherosclerosis$702,356
R01 · FY2017 · HL
Synthetic HDL_a potential sepsis therapy$603,893
R01 · FY2017 · GM
Synthetic HDL_a potential sepsis therapy$603,893
R01 · FY2016 · GM
Synthetic HDL_a potential sepsis therapy$616,222
R01 · FY2015 · GM